Related Experiment Video
Updated: Jun 19, 2026
03:55
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
Angiogenic study in Graves' disease treated with thyroid arterial embolization.
Wei Zhao1, Bu-Lang Gao, Zhi-Yong Liu
1Kunming Medical College, Kunming, People's Republic of China.
Summary
Thyroid arterial embolization reduces vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and microvessel density (MVD) in Graves' disease. This decrease in angiogenesis leads to long-term reduction in thyroid size and function.
Area of Science:
- Endocrinology
- Vascular Biology
- Interventional Radiology
Background:
- Graves' disease (GD) is an autoimmune disorder characterized by thyroid hyperactivity.
- Angiogenesis plays a crucial role in the pathophysiology of GD.
- Thyroid arterial embolization is a therapeutic option for managing GD.
Purpose of the Study:
- To investigate the impact of thyroid arterial embolization on angiogenesis in GD.
- To analyze changes in vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and microvessel density (MVD) post-embolization.
Main Methods:
- Forty-two GD patients underwent thyroid arterial embolization.
- Thyroid function tests and thyroid stimulating antibody (TSAb) levels were monitored.
- Thyroid biopsies analyzed VEGF, bFGF expression, and MVD (CD34 staining) via immunohistochemistry.
Main Results:
- VEGF expression increased early post-embolization, then decreased significantly after one year.
- bFGF expression showed a significant decrease after one year.
- MVD changes mirrored VEGF expression, with positive correlations between VEGF, bFGF, and MVD.
- Thyroid hormones normalized, and TSAb levels decreased with longer follow-up.
Conclusions:
- Thyroid arterial embolization effectively reduces VEGF, bFGF, and MVD in GD patients.
- This reduction in angiogenesis contributes to long-term decrease in thyroid size and function.
- Embolization offers a potential therapeutic strategy for controlling GD by modulating thyroid vascularity.
Related Concept Videos
01:24Graves Disease II: Pathophysiology
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
01:28Graves' Disease I: Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:27Goiter
Goiter refers to an abnormal enlargement of the thyroid gland that may appear as a diffuse goiter (uniform enlargement) or nodular (single or multiple nodules). Functionally, it is classified as nontoxic (normal/low hormone levels) or toxic (excess hormone production).PathophysiologyDiffuse thyroid enlargement typically results from prolonged stimulation by thyroid-stimulating hormone (TSH) or TSH-like agents, commonly seen in hypothyroidism or iodine deficiency. In contrast, in hyperthyroid...
01:25Hyperthyroidism I: Introduction
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
01:23The Thyroid Gland
The thyroid gland is a small, butterfly-shaped gland located in the neck and covers the anterior surface of the trachea. The gland has two lateral lobes connected by a thin tissue mass called the isthmus. Internally, each lobe comprises many small spherical structures known as thyroid follicles, surrounded by a network of blood vessels.
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...